Fibroblast Growth Factor 9 (FGF9) is a secreted signaling protein belonging to the fibroblast growth factor family, which plays critical roles in embryonic development, tissue repair, and metabolic regulation. It binds to fibroblast growth factor receptors (FGFRs) with a preference for FGFR2 and FGFR3. activating downstream signaling pathways such as MAPK and PI3K-AKT to regulate cell proliferation, differentiation, and survival. FGF9 is notably involved in organogenesis, particularly in lung branching morphogenesis, limb development, and skeletal formation. Dysregulation of FGF9 expression is linked to various pathologies, including cancers (e.g., gastric, colorectal), skeletal disorders, and pulmonary diseases.
FGF9 antibodies are immunological tools designed to detect, quantify, or inhibit FGF9 in experimental and clinical contexts. Polyclonal or monoclonal antibodies are generated using recombinant FGF9 proteins or peptide epitopes. These antibodies enable researchers to study FGF9's spatial-temporal expression via techniques like Western blotting, immunohistochemistry, and immunofluorescence. Neutralizing antibodies, which block FGF9-receptor interactions, are explored for therapeutic applications in cancer and fibrosis. Additionally, FGF9 antibodies aid in elucidating molecular mechanisms in disease models, such as abnormal bone growth or tumor angiogenesis. Their specificity and affinity are validated through epitope mapping and functional assays to ensure reliability in research and diagnostics.